Your browser is no longer supported. Please, upgrade your browser.
BIIB [NASD]
Biogen Inc.
IndexS&P 500 P/E20.78 EPS (ttm)19.06 Insider Own0.10% Shs Outstand151.90M Perf Week0.18%
Market Cap62.35B Forward P/E18.89 EPS next Y20.97 Insider Trans-6.10% Shs Float149.58M Perf Month41.35%
Income3.01B PEG- EPS next Q4.57 Inst Own86.90% Short Float2.10% Perf Quarter52.39%
Sales12.60B P/S4.95 EPS this Y-21.10% Inst Trans-1.22% Short Ratio1.82 Perf Half Y64.06%
Book/sh70.32 P/B5.63 EPS next Y12.54% ROA12.20% Target Price287.87 Perf Year41.83%
Cash/sh16.12 P/C24.57 EPS next 5Y-7.60% ROE27.70% 52W Range223.25 - 468.55 Perf YTD61.76%
Dividend- P/FCF18.13 EPS past 5Y10.10% ROI19.60% 52W High-15.47% Beta0.40
Dividend %- Quick Ratio1.80 Sales past 5Y4.50% Gross Margin85.50% 52W Low77.42% ATR20.87
Employees9100 Current Ratio2.10 Sales Q/Q-23.80% Oper. Margin29.40% RSI (14)75.36 Volatility5.55% 6.51%
OptionableYes Debt/Eq0.00 EPS Q/Q-66.70% Profit Margin23.90% Rel Volume1.10 Prev Close406.14
ShortableYes LT Debt/Eq0.68 EarningsApr 22 BMO Payout0.00% Avg Volume1.73M Price396.08
Recom2.80 SMA2026.17% SMA5037.62% SMA20045.93% Volume1,896,950 Change-2.48%
Jun-14-21Reiterated Truist Buy $458 → $647
Jun-11-21Upgrade Bernstein Mkt Perform → Outperform $500
Jun-10-21Upgrade UBS Neutral → Buy
Jun-08-21Upgrade William Blair Mkt Perform → Outperform
Jun-08-21Upgrade Robert W. Baird Underperform → Neutral $216 → $382
Jun-08-21Upgrade Citigroup Sell → Neutral $200 → $440
Jun-08-21Upgrade Atlantic Equities Underweight → Neutral $415
Jun-08-21Reiterated Stifel Buy $346 → $446
Jun-08-21Reiterated RBC Capital Mkts Sector Perform $259 → $400
Jun-08-21Reiterated Morgan Stanley Overweight $343 → $455
Jun-08-21Reiterated Jefferies Buy $450 → $500
Jun-08-21Reiterated H.C. Wainwright Buy $305 → $452
Jun-08-21Reiterated Barclays Equal Weight $265 → $395
Jun-07-21Upgrade Raymond James Underperform → Mkt Perform
Jun-07-21Upgrade Cowen Market Perform → Outperform $225 → $450
Jun-07-21Upgrade BofA Securities Underperform → Neutral $235 → $400
Feb-05-21Downgrade DZ Bank Buy → Hold $264
Jan-29-21Upgrade Stifel Hold → Buy $258 → $358
Nov-10-20Upgrade DZ Bank Hold → Buy $265
Nov-09-20Reiterated H.C. Wainwright Buy $318 → $289
Jun-15-21 04:17PM  
10:55AM  
10:35AM  
09:56AM  
09:55AM  
09:37AM  
08:52AM  
07:16AM  
07:12AM  
06:56AM  
06:46AM  
06:30AM  
06:05AM  
03:36AM  
01:43AM  
Jun-14-21 04:06PM  
12:57PM  
12:07PM  
11:10AM  
03:00AM  
Jun-13-21 09:03AM  
06:15AM  
05:28AM  
Jun-11-21 06:47PM  
04:31PM  
04:15PM  
04:07PM  
02:27PM  
01:19PM  
12:31PM  
12:18PM  
09:50AM  
08:55AM  
06:45AM  
06:39AM  
12:58AM  
Jun-10-21 08:00PM  
07:59PM  
05:58PM  
05:08PM  
04:19PM  
04:06PM  
07:30AM  
06:43AM  
Jun-09-21 03:53PM  
11:43AM  
04:02AM  
Jun-08-21 07:33PM  
06:28PM  
04:05PM  
04:04PM  
03:34PM  
03:18PM  
02:27PM  
12:27PM  
12:14PM  
10:31AM  
10:29AM  
10:15AM  
10:09AM  
10:02AM  
09:36AM  
08:46AM  
08:42AM  
08:41AM  
08:24AM  
08:20AM  
07:51AM  
07:12AM  
06:43AM  
06:14AM  
06:03AM  
05:52AM  
03:28AM  
01:07AM  
01:05AM  
Jun-07-21 08:00PM  
06:16PM  
06:12PM  
05:45PM  
05:18PM  
05:05PM  
04:40PM  
04:33PM  
04:26PM  
04:22PM  
04:15PM  
04:13PM  
04:08PM  
03:51PM  
02:48PM  
02:31PM  
02:00PM  
01:51PM  
01:01PM  
01:00PM  
12:45PM  
12:43PM  
12:30PM  
11:58AM  
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company offers products through its sales force and marketing groups. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; and Ionis Pharmaceuticals, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sandrock AlfredHead of Research & DevelopmentJun 07Sale440.007,6723,375,68010,169Jun 09 07:05 PM
Guindo ChirfiHead of Glob Prod Strat & ComJun 07Sale440.003,0871,358,2802,919Jun 09 07:04 PM
Posner Brian SDirectorJun 04Sale274.1736098,7017,400Jun 07 07:02 PM
Sandrock AlfredEVP, Research & DevelopmentFeb 12Option Exercise0.004,454019,715Feb 17 05:01 PM
Vounatsos MichelChief Executive OfficerFeb 12Option Exercise0.0016,289060,194Feb 17 05:03 PM
Kramer RobinSVP, Chief Accounting OfficerFeb 12Option Exercise0.003330706Feb 17 04:59 PM
Guindo ChirfiEVP Glob. Prod Strat and CommFeb 12Option Exercise0.003,15606,946Feb 17 04:58 PM
Gregory GingerEVP, Human ResourcesFeb 12Option Exercise0.002,92309,288Feb 17 04:56 PM
Galdes AlphonseEVP Pharmaceutical Oper & TechFeb 12Option Exercise0.001,57304,765Feb 17 04:54 PM
ALEXANDER SUSAN HEVP Chief Legal Off & Corp SecFeb 12Option Exercise0.004,355043,509Feb 17 04:52 PM
Mantas Jesus BDirectorFeb 09Buy267.00898239,7662,943Feb 10 04:31 PM
Kramer RobinVP, Chief Accounting OfficerDec 03Option Exercise0.00740395Dec 07 09:08 PM
Guindo ChirfiEVP Glob. Prod Strat and CommDec 01Option Exercise0.0048104,004Dec 03 05:41 PM
Vounatsos MichelChief Executive OfficerNov 30Buy241.313,100748,04734,810Dec 01 04:57 PM
Sandrock AlfredEVP, Research & DevelopmentNov 04Sale350.001,500525,00013,066Nov 06 09:39 PM
Gregory GingerEVP, Human ResourcesJul 31Option Exercise0.0021204,786Aug 04 04:12 PM